Pick 2–10 funds, stocks or ETFs to see their returns, risk, costs and highlights on one page
| Fund | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| NTRA | +65.40% | −6.42% | −5.13% | −7.66% | +41.51% | +82.81% | +90.48% | +834.45% | +232.07% | +263.26% |
| ES-GENOME | +62.79% | +0.74% | +3.41% | −8.31% | +27.43% | +59.28% | +52.50% | +72.28% | −45.83% | −53.44% |
| BCARE | +14.91% | +1.99% | +5.09% | +8.23% | +8.14% | +17.30% | +23.16% | +33.14% | +7.17% | +16.51% |
| KT-HEALTHCARE-A | +11.77% | +2.76% | +5.34% | +7.46% | +5.05% | +15.11% | +19.81% | +42.07% | +16.93% | +29.40% |
* Fewer than 12 months: the year the fund started reporting NAV, or the current year
Counts only the top holdings with available data, not the whole portfolio · Pick a pair below for details
Excludes NTRA: money market or bond funds, or no holdings data yet
| BCARE | KT-HEALTHCARE-A | |
|---|---|---|
| Held by both | ||
 Eli Lilly and Co | 8.44% | 9.58% |
 Johnson & Johnson | 4.76% | 7.75% |
 AstraZeneca | 3.87% | 3.70% |
 Unitedhealth Group | 2.88% | 4.26% |
 ABBVIE | 2.48% | 4.91% |
 Merck & | 5.46% | 2.34% |
| Only in BCARE | ||
 GSK | 2.48% | N/A |
 Intuitive Surgical | 2.38% | N/A |
 Vertex Pharmaceuticals | 2.28% | N/A |
 Elevance Health | 2.28% | N/A |
| Only in KT-HEALTHCARE-A | ||
 Thermo Fisher | N/A | 3.34% |
 Novartis | N/A | 2.72% |
 Roche | N/A | 2.67% |
 argenx | N/A | 2.44% |
30 Dec 2025 → 2 Nov 2026
| Fund | Return per year | Volatility per year | Sharpe |
|---|---|---|---|
| ES-GENOME | +62.79% | 42.39% | 1.48 |
| NTRA | +65.40% | 52.61% | 1.24 |
| BCARE | +14.91% | 15.93% | 0.94 |
| KT-HEALTHCARE-A | +11.77% | 16.77% | 0.70 |
Sharpe here = annual return ÷ annual volatility, without deducting the risk-free rate, calculated from NAV over the selected period · Periods shorter than 1 year use the cumulative return instead of the annual return
| Drag a column header to reorder | NTRA | ES-GENOME | BCARE | KT-HEALTHCARE-A |
|---|---|---|---|---|
Fund details | ||||
| Fund size | N/A | 225 million | 4,712 million | 1,871 million |
| Inception date | N/A | 23 Mar 2021 | 29 Aug 2007 | 27 Nov 2015 |
| Master fund | N/A | กองทุนที่ลงทุนหลายกอง (ARK Genomic Revolution UCITS, ARK Genomic Revolution, iShares Genomics Immunology and Healthcare) | Wellington Global Health Care Equity Fund | Janus Henderson Global Life Sciences Fund |
| Dividend policy | N/A | Does not pay | Does not pay | Does not pay |
Risk and currency hedging | ||||
| Risk level | N/A | 7 | 7 | 7 |
| Hedging policy | N/A | Hedged at the manager's discretion | Hedged at the manager's discretion | Varies by share class |
| Share hedged | N/A | 79.06% | 47.41% | 68.69% |
Minimum purchase and redemption | ||||
| First purchase | N/A | 1 THB | 500 THB | 1 THB |
| Subsequent purchase | N/A | 1 THB | 500 THB | 1 THB |
| Redemption (amount) | N/A | 1 THB | No minimum | No minimum |
| Redemption (units) | N/A | 1 units | No minimum | No minimum |
| Balance (amount) | N/A | No minimum | No minimum | No minimum |
| Balance (units) | N/A | No minimum | No minimum | No minimum |
Order cut-off and redemption payment | ||||
| Buy before | N/A | 15:30 | 15:30 | 15:30 |
| Redeem before | N/A | 15:30 | 15:30 | 15:30 |
| Redemption paid | N/A | T+4 | T+4 | T+4 |
